menu
    • menu
    [{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GEN6050","moa":"DMD exon 50","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou GenAssist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"GEN6050X","moa":"E50","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou GenAssist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"RAG-06","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ractigen Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ SDIC CS Capital","highestDevelopmentStatusID":"5","companyTruncated":"Ractigen Therapeutics \/ SDIC CS Capital"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"ViGeneron","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"WuXi Biologics \/ ViGeneron","highestDevelopmentStatusID":"5","companyTruncated":"WuXi Biologics \/ ViGeneron"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Suzhou GenAssist Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed

                            Suzhou GenAssist Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN6050X

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GenAssist’s GEN6050X IND Cleared by FDA for Duchenne Muscular Dystrophy

                            Details : GEN6050X, a globally first-in-class base editing drug, which is currently being evaluated for the treatment of duchenne muscular dystrophy.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : GEN6050X

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Suzhou GenAssist Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed

                            Suzhou GenAssist Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN6050

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Suzhou GenAssist Therapeutic Co.,Ltd Recently Announced that Its First Base Editing Product, GEN6050, Has Subm...

                            Details : GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular dystrophy (DMD) gene. It is designed to restore the expression of dystrophin protein by base editing.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : GEN6050

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ractigen Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-06

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : SDIC CS Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Closes an Additional $30 Million in Series A+ Funding to Push Development of Its RNAa Pl...

                            Details : Ractigen will use this capital to advance several programs from preclinical to clinical phase, as well as scale-up its oligonucleotide manufacturing capabilities including its lead product RAG-06.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : RAG-06

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : SDIC CS Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CANbridge Pharmaceuticals

                            China arrow
                            COMPAMED
                            Not Confirmed

                            CANbridge Pharmaceuticals

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : glucocerebrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gauch...

                            Details : CAN103 is an enzyme replacement therapy (ERT) being developed by CANbridge as part of its rare disease partnership with WuXi Biologics (2269.HK) for the long-term treatment of adults and children with Gaucher disease, Types I and III.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 20, 2021

                            Lead Product(s) : glucocerebrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CANbridge Pharmaceuticals

                            China arrow
                            COMPAMED
                            Not Confirmed

                            CANbridge Pharmaceuticals

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : glucocerebrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : WuXi Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical P...

                            Details : CAN103 is an enzyme replacement therapy (ERT) being developed by CANbridge as part of its rare disease partnership with WuXi Biologics (2269.HK) for the long-term treatment of adults and children with Gaucher disease, Types I and III.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            August 02, 2021

                            Lead Product(s) : glucocerebrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : WuXi Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            WuXi Biologics

                            China arrow
                            COMPAMED
                            Not Confirmed

                            WuXi Biologics

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG901

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : ViGeneron

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic...

                            Details : WuXi ATU will accelerate the development of VG901 by manufacturing, testing and making available the clinical trial grade treatment while leveraging its trusted, world-class AAV Suspension and Plasmid DNA platforms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 01, 2020

                            Lead Product(s) : VG901

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : ViGeneron

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth